Nociceptin and the
nociceptin receptor (NOP) have been described as targets for treatment of
pain and
inflammation, whereas
toll-like receptors (TLRs) play key roles in
inflammation and impact
opioid receptors and endogenous
opioids expression. In this study, interactions between the
nociceptin and TLR systems were investigated. Human THP-1 cells were cultured with or without
phorbol myristate acetate (PMA 5 ng/mL), agonists specific for TLR2 (
lipoteichoic acid, LTA 10 µg/mL), TLR4 (
lipopolysaccharide, LPS 100 ng/mL), TLR7 (
imiquimod, IMQ 10 µg/mL), TLR9 (
oligonucleotide (ODN) 2216 1 µM), PMA+TLR agonists, or
nociceptin (0.01−100 nM).
Prepronociceptin (ppNOC), NOP, and TLR mRNAs were quantified by RT-qPCR.
Proteins were measured using flow cytometry. PMA upregulated ppNOC
mRNA, intracellular
nociceptin, and cell membrane NOP
proteins (all p < 0.05). LTA and LPS prevented PMA’s upregulating effects on ppNOC
mRNA and
nociceptin protein (both p < 0.05). IMQ and ODN 2216 attenuated PMA’s effects on ppNOC
mRNA. PMA, LPS, IMQ, and ODN 2216 increased NOP
protein levels (all p < 0.05). PMA+TLR agonists had no effects on NOP compared to PMA controls.
Nociceptin dose-dependently suppressed TLR2, TLR4, TLR7, and TLR9
proteins (all p < 0.01). Antagonistic effects observed between the
nociceptin and TLR systems suggest that the
nociceptin system plays an anti-inflammatory role in monocytes under inflammatory conditions.